Shandong Bailong Chuangyuan Bio-Tech (605016)
- 21.50
- -0.34-1.56%
Shandong Bailong Chuangyuan Bio-Tech (605016) News
GF Securities: The baijiu sector is poised to enter a new growth cycle this year, and average selling prices in the mass-market consumer goods industry are expected to see moderate increases.
Certain sub-sectors within mass-market consumer goods have already shown signs of stabilization in 2025. Looking ahead to 2026, industry-average price per ton is expected to experience a modest increase, and we are optimistic about stock-specific opportunities driven by new products and new distribution channels.
Bailong Chuangyuan plans a RMB 1.123 billion expansion to boost functional sugar production, but the first batch of companies racing to secure 'sugar energy' have yet to attract customers.
Allulose is riding the tailwind, with capacity expansion outpacing demand.
Bailong Chuangyuan (605016): A leading, high-growth player in functional food ingredients.
Bailong Chuangyuan: a leading domestic manufacturer of functional food ingredients. Founded in 2005, the company's product portfolio currently focuses on prebiotic series, dietary fiber series, healthy sweeteners, and other starch sugars (alcohols), with the capability to produce over 200 different products.
Bailong Chuangyuan (605016.SH) 2025 Annual Dividend Distribution: RMB 0.165 per share
Gelonghui, May 26 — Bailong Chuangyuan (SHA: 605016) announced its 2025 annual profit distribution implementation notice. The dividend distribution is based on the company's total share capital of 420,012,320 shares prior to the implementation of the plan, with a cash dividend of RMB 0.165 per share (inclusive of tax), amounting to a total cash dividend of RMB 69,302,032.80. The record date for this equity distribution is June 1, 2026, and the ex-dividend date is June 2, 2026.
Bailong Chuangyuan (605016): Profitability Continues to Improve; New Markets and Increased Production Capacity Hold Promising Growth Prospects
Event Description: On April 8 and April 30, the company released its 2025 annual report and its Q1 2026 report, respectively. For the full year 2025, the company reported operating revenue of RMB 1.379 billion, up 19.75% year over year; net profit attributable to…
Bailong Chuangyuan (605016): Quarterly Results Hit a New High; Product Sales Continue to Grow
The company released its Q1 2026 financial report, reporting total operating revenue of RMB 390 million, up 25.3% year over year; net profit attributable to shareholders of RMB 120 million, up 48.1% year over year; and non‑GAAP net profit of RMB 120 million.
Shanghai Bourse Accepts Bailong Chuangyuan Bio-Tech's Convertible Bond Issuance Application
The Shanghai Stock Exchange accepted Shandong Bailong Chuangyuan Bio-Tech's (SHA:605016) application to issue convertible corporate bonds, according to a Shanghai bourse disclosure on Wednesday.The
Research Report Insights | ZHONGYOU Securities: Strong demand for healthy consumption supports profit growth at Bailong Chuangyuan, with ongoing capacity expansion progressing steadily.
Gelonghui, May 6 | A research report by Zhongyou Securities pointed out that Bailong Chuangyuan's profitability is supported by the rigid demand for health consumption, and its ongoing capacity expansion projects are proceeding as planned. In the first quarter of 2026, the company achieved operating revenue of 393 million yuan, representing a year-on-year increase of 25.32% and a quarter-on-quarter decrease of 4.28%; net profit attributable to shareholders of the listed company amounted to 121 million yuan, reflecting a year-on-year growth of 48.10% and a quarter-on-quarter increase of 16.03%. The approval of allulose has opened up industrialization opportunities, with the rigid demand for health consumption continuing to support profit growth. The company’s current construction projects are advancing steadily, with a clear direction for capacity expansion and international transformation. 'Functional sugar drying capacity expansion and comprehensive enhancement.'
Bailong Chuangyuan (605016): Steady Profit Growth Supported by Inelastic Demand for Health Consumption, with Construction-Underway Capacity Progressing Smoothly
On April 30, 2026, Bailong Chuangyuan released its first-quarter report for 2026. In the first quarter of 2026, the company recorded operating revenue of RMB 393 million, up 25.32% year on year but down 4.28% quarter on quarter.
Bailong Chuangyuan (605016): Continuous Premiumization of Dietary Fiber Product Mix; Allulose Volumes and Margins Both Rise; Performance Maintains High Growth
The company released its Q1 2026 earnings report, with results in line with expectations. In Q1 2026, the company reported revenue of RMB 393 million (up 25% year over year and down 4% quarter over quarter) and net profit attributable to owners of the parent company of RMB 121 million (up 48% year over year).
Bailong Chuangyuan (605016) Q1 2026 Earnings Review: Strong Structural Performance and Sustained Growth
Executive Summary of This Report: In Q1 2026, the company continued to optimize its product mix, with increased production of high-margin products such as resistant dextrin driving a further significant improvement in profitability, suggesting sustained growth going forward. Key Investment Points: Investment Recommendation: Maintain an "Add" rating. Maintain the comp
Bailong Innovation Park: First Quarter Report for 2026
Announcement on Key Operating Data for the First Quarter of 2026
First Quarter Report for 2026
Bailong Chuangyuan (605016): Strong Year-on-Year Revenue Growth in 2025, with Q1 2026 Results Reaching a New High
The company released its 2025 annual report, reporting total operating revenue of RMB 1.379 billion for the year, up 19.75% year on year; net profit attributable to owners of the parent company of RMB 369 million, up 50.06% year on year; and net profit attributable to owners of the parent company after deducting non-recurring items of RMB 363 million.
GF Securities: It is expected that the performance adjustment for baijiu will continue, while the per-ton price of mass-market products is likely to experience a moderate increase.
The baijiu sector, after undergoing a four-year adjustment period, is expected to enter a new development phase in 2026.
Results: Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Shareholders of Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (SHSE:605016) will be pleased this week, given that the stock price is up 12% to CN¥28.07 following its latest yearly results.
Bailong Chuangyuan (605016): Record First-Quarter 2026 Results, with Strong Momentum for Rapid Growth
Event: The company disclosed its 2025 annual report and the preliminary results for Q1 2026. For the full year 2025, the company achieved revenue of RMB 1.379 billion, up 19.75% year on year; net profit attributable to owners of the parent company was RMB 369 million, up 50.06% year on year. Among them, 2
Bailong Chuangyuan (605016): Growth and Upgrading Jointly Drive Profit Margins to Break Higher
In 2025, revenue, net profit attributable to parent company shareholders, and net profit attributable to parent company shareholders after deducting non-recurring items were RMB 1.38 billion, RMB 370 million, and RMB 360 million, respectively, representing year-on-year growth of 19.7%, 50.1%, and 57.1%. Correspondingly, for Q4 2025, revenue, net profit attributable to parent company shareholders, and net profit attributable to parent company shareholders after deducting non-recurring items...
Bailong Chuangyuan (605016) Review: Concurrent Growth in Dietary Fiber, Healthy Sweeteners, and Prebiotics Drives Sustained High Revenue Expansion
Investment Highlights: The company released its 2025 annual report, with results in line with expectations. In 2025, the company achieved operating revenue of RMB 1.379 billion (up 20% year on year) and net profit attributable to shareholders of RMB 369 million (up 50% year on year), excluding non-recurring items.